Alternative Splicing and Leukemia Initiating Cells
ASLIC
1 other identifier
observational
500
1 country
1
Brief Summary
Aberrant RNA splicing and mutations in spliceosome complex in acute myeloid leukaemia (AML) are frequent. It have been shown that some splicing variants had a prognostic value in AML. AML are characterized by their propensity to relapse because of the persistence of leukaemia initiating cells (LICs). The aim of this study is to determine the splice variants on AML initiator cells and define a splicing pattern.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2017
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2017
CompletedFirst Submitted
Initial submission to the registry
April 4, 2017
CompletedFirst Posted
Study publicly available on registry
May 17, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2018
CompletedMay 17, 2017
April 1, 2017
11 months
April 4, 2017
May 16, 2017
Conditions
Outcome Measures
Primary Outcomes (2)
Polymerase chain reaction
Transcriptome analysis to determine the splicing variants on acute myeloid leukaemia initiator cells. The analysis will focus on the gene encoding ABCA3 transporter and genes known to be mutated in patients with acute myeloid leukemia (FLT3, NPM1, c-Kit, N et K-RAS). The duration of selection of samples is estimated to be one month.
1 month
Ribonucleic acid sequencing
Transcriptome analysis to determine the splicing variants on acute myeloid leukaemia initiator cells. The analysis will focus on the gene encoding ABCA3 transporter and genes known to be mutated in patients with acute myeloid leukemia (FLT3, NPM1, c-Kit, N et K-RAS). The duration of selection of samples is estimated to be one month.
1 month
Study Arms (1)
Splicing variants
Sample of acute myeloid leukaemia primary cells
Interventions
This is a biological study with primary samples without any intervention on patients.
Eligibility Criteria
Patients with 11q23 acute myeloid leukaemia
You may qualify if:
- Age ≥ 18 years-old
- Patients treated at the south lyon hospital center
- Patients with a diagnosis of acute myeloid leukemia confirmed in cytology and whose involvement of the 11q23 locus was confirmed by in situ hybridization
- Patients for whom a sample is available in the cytogenetic laboratory of the south lyon hospital center
You may not qualify if:
- None
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Service d'hématologie du Centre Hospitalier Lyon Sud
Pierre-Bénite, 69310, France
Biospecimen
RNA
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Etienne PAUBELLE, MD, PhD
Service d'hématologie du Centre Hospitalier Lyon Sud
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 4, 2017
First Posted
May 17, 2017
Study Start
April 1, 2017
Primary Completion
March 1, 2018
Study Completion
April 1, 2018
Last Updated
May 17, 2017
Record last verified: 2017-04